Scarica l'app Stockscreener
79.93
0.15%
-0.12
Dopo l'orario di chiusura:
79.75
-0.18
-0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$80.05
Aprire:
$80.055
Volume 24 ore:
4.86M
Relative Volume:
1.09
Capitalizzazione di mercato:
$247.89B
Reddito:
$56.53B
Utile/perdita netta:
$8.32B
Rapporto P/E:
29.83
EPS:
2.6798
Flusso di cassa netto:
$8.49B
1 W Prestazione:
-0.73%
1M Prestazione:
+10.01%
6M Prestazione:
+5.66%
1 anno Prestazione:
-8.35%
Intervallo 1D:
$79.47
$80.26
Intervallo di 1 settimana:
$79.38
$81.56
Portata 52W:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
79.93 | 246.98B | 56.53B | 8.32B | 8.49B | 2.6798 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
University of Michigan Suit Targets AstraZeneca FluMist Profits - Bloomberg Law News
AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO [Video] - AOL.com
Global Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight - GlobeNewswire Inc.
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
Va. backs big pharma deals for AstraZeneca in Albemarle, Eli Lilly in Goochland - Richmond Times-Dispatch
Evaluating AstraZeneca PLC Depositary Receipt with trendline analysis2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
Tools to monitor AstraZeneca PLC Depositary Receipt recovery probabilityWeekly Market Report & Weekly Top Gainers Alerts - Newser
AstraZeneca bounces back from scandal in China - Financial Times
AstraZeneca PLC Depositary Receipt Recovery Hinges on Volume Breakout getLinesFromResByArray error: size == 0 - 더경남뉴스
AstraZeneca Sees Increase in Voting Rights by The Capital Group - TipRanks
What candlestick patterns are forming on AstraZeneca PLC Depositary Receipt2025 Market Outlook & Daily Stock Trend Watchlist - Newser
Published on: 2025-08-26 09:01:55 - Newser
Is a relief rally coming for AstraZeneca PLC Depositary Receipt holdersWeekly Profit Analysis & Reliable Volume Spike Trade Alerts - Newser
Multi asset correlation models including AstraZeneca PLC Depositary Receipt2025 Macro Impact & Breakout Confirmation Trade Signals - Newser
AstraZeneca PLC ADR falls Monday, underperforms market - MarketWatch
AstraZeneca’s New NSCLC Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Daiichi Sankyo and AstraZeneca’s Datroway receives approval in China - Pharmaceutical Technology
Is it time to cut losses on AstraZeneca PLC Depositary ReceiptPrice Action & Stock Market Timing Techniques - Newser
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca’s New Asthma Study: Potential Market Impact - TipRanks
AstraZeneca’s New Study on Tezepelumab for CRSwNP: A Potential Game-Changer - TipRanks
Amgen and AstraZeneca Launch Promising Phase 3 Lung Cancer Study - TipRanks
AstraZeneca’s Innovative Lung Cancer Screening Study: A Game Changer for Early Detection - TipRanks
AstraZeneca’s ARISE Study: Real-World Insights on Acalabrutinib for CLL - TipRanks
AstraZeneca’s DESTINY-Endometrial01 Study: A New Horizon in Endometrial Cancer Treatment - TipRanks
AstraZeneca’s AZD9829 Study: A New Hope in Hematological Cancer Treatment - TipRanks
AstraZeneca’s GEMINI-PeriOp GC Study: A New Frontier in Gastroesophageal Cancer Treatment - TipRanks
AstraZeneca’s CHRONICLES COPD Study: A New Horizon in COPD Treatment - TipRanks
AstraZeneca’s New CAR T-Cell Therapy Study: A Potential Game-Changer for Multiple Myeloma - TipRanks
AstraZeneca’s New Study on Crohn’s Disease Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s Phase III COPD Study: A Potential Game-Changer in Respiratory Treatment - TipRanks
Earnings call transcript: AstraZeneca’s Q2 2025 earnings exceed expectations - Investing.com
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
AstraZeneca’s Benralizumab Study Completes: A Potential Game-Changer for COPD Treatment - TipRanks
AstraZeneca’s Phase 3 Study on Advanced Biliary Tract Cancer: A Potential Game-Changer? - TipRanks
AstraZeneca’s Atuliflapon Study: A New Hope for Uncontrolled Asthma - TipRanks
AstraZeneca’s Saruparib Study: A New Frontier in Cancer Treatment? - TipRanks
AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? - TipRanks
AstraZeneca advances Wednesday, outperforms market - MarketWatch
AstraZeneca’s New Asthma Treatment Study: What Investors Should Know - TipRanks
Fitch Upgrades AstraZeneca on Profit Growth; Ratings Withdrawn for Commercial Reasons - MarketScreener
AstraZeneca’s Benralizumab Study: A Step Forward in COPD Treatment - TipRanks
Risk adjusted return profile for AstraZeneca PLC Depositary Receipt analyzed2025 Risk Factors & Intraday High Probability Alerts - Newser
AstraZeneca’s Promising Asthma Treatment: A Closer Look at the Atuliflapon Study - TipRanks
AstraZeneca’s Phase I Study on Saruparib: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s New Study on Advanced Biliary Tract Cancer: A Potential Game Changer? - TipRanks
AstraZeneca Receives Chinese Approval to Acquire FibroGen China - MarketScreener
AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Market Game-Changer - MSN
AstraZeneca CFO Aradhana Sarin sells 9,563 shares in London transaction - Investing.com
AstraZeneca’s New Study on T-DXd Offers Hope for HER2-Positive Tumor Patients - MSN
AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination - Yahoo Finance
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):